Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term effect of fampridine on cognition and function in multiple sclerosis
IRCT20161212031362N4Phase 3Completed
- Sponsor
- Iranian Center of Neurological Research
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Fampridine with Placebo (2 arms). Primary endpoint: Change in SDMT test score. Started May 2024; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20161212031362N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20161212031362N4.